BioSavita
About:
BioSavita's high throughput synthetic DNA technologies and yeast strains enable the rapid manufacture of fully functional antibodies,
Website: http://biosavita.com/
Description:
BioSavita's high throughput synthetic DNA technologies and yeast strains enable the rapid manufacture of fully functional antibodies, single domain antibodies, antibody-drug conjugates and fusion proteins. They are focused on developing novel biological drugs and vaccines in partnership with biopharmaceutical companies and government agencies.
Total Funding Amount:
$3M
Estimated Revenue Range:
Less than $1M
Headquarters Location:
Plymouth, Michigan, United States
Founded Date:
1994-06-01
Founders:
Nalini Motwani
Number of Employees:
1-10
Last Funding Date:
2014-10-17
IPO Status:
Private
Industries:
© 2025 bioDAO.ai